These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
140 related items for PubMed ID: 33196286
1. Variation in generic dispensing rates in Medicare Part D. Buttorff C, Xu Y, Joyce G. Am J Manag Care; 2020 Nov 01; 26(11):e355-e361. PubMed ID: 33196286 [Abstract] [Full Text] [Related]
3. Trends in Medicare Part D coverage of generics with equivalent brand-name drugs. Dusetzina SB, Cubanski J, Roberts AW, Hoadley J, True S, Nshuti L, Neuman T. Am J Manag Care; 2021 Jul 01; 27(7):283-288. PubMed ID: 34314117 [Abstract] [Full Text] [Related]
4. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available. Dusetzina SB, Cubanski J, Nshuti L, True S, Hoadley J, Roberts D, Neuman T. Health Aff (Millwood); 2020 Aug 01; 39(8):1326-1333. PubMed ID: 32744944 [Abstract] [Full Text] [Related]
5. Impact of cost sharing on prescription drugs used by Medicare beneficiaries. Goedken AM, Urmie JM, Farris KB, Doucette WR. Res Social Adm Pharm; 2010 Jun 01; 6(2):100-9. PubMed ID: 20511109 [Abstract] [Full Text] [Related]
9. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing. Bazalo G, Weiss RC. Consult Pharm; 2012 Apr 01; 27(4):269-73. PubMed ID: 22498986 [Abstract] [Full Text] [Related]
10. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare. Cortese BD, Dusetzina SB, Luckenbaugh AN, Al Hussein Al Awamlh B, Stimson CJ, Barocas DA, Penson DF, Chang SS, Talwar R. J Clin Oncol; 2023 Oct 10; 41(29):4664-4668. PubMed ID: 37290029 [Abstract] [Full Text] [Related]
11. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit. Sheingold S, Nguyen NX. Medicare Medicaid Res Rev; 2014 Oct 10; 4(1):. PubMed ID: 24918023 [Abstract] [Full Text] [Related]
12. Measuring economic impact of applying daily average consumption limits. Flavin BM, Nishida LM, Karbowicz SH, Renner ME, Leonard RJ. J Manag Care Pharm; 2014 Feb 10; 20(2):159-64. PubMed ID: 24456317 [Abstract] [Full Text] [Related]
15. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study. Duru OK, Ettner SL, Turk N, Mangione CM, Brown AF, Fu J, Simien L, Tseng CW. J Gen Intern Med; 2014 Jan 10; 29(1):230-6. PubMed ID: 23975059 [Abstract] [Full Text] [Related]
16. Medicare coverage of buprenorphine-naloxone film surrounding generic entry. Zhang H, Bao Y, Kapadia SN. Am J Manag Care; 2023 Aug 01; 29(8):e257-e260. PubMed ID: 37616154 [Abstract] [Full Text] [Related]
17. Impact of medicare part D plan features on use of generic drugs. Tang Y, Gellad WF, Men A, Donohue JM. Med Care; 2014 Jun 01; 52(6):541-8. PubMed ID: 24824538 [Abstract] [Full Text] [Related]
18. Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program. Ma I, Tisdale RL, Vail D, Heidenreich PA, Sandhu AT. Circ Cardiovasc Qual Outcomes; 2021 Dec 01; 14(12):e007559. PubMed ID: 34879702 [Abstract] [Full Text] [Related]
19. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents. Sacks CA, Lee CC, Kesselheim AS, Avorn J. JAMA; 2018 Aug 21; 320(7):650-656. PubMed ID: 30140875 [Abstract] [Full Text] [Related]